Prostemics Co. Ltd
Ark Solutions Inc. engages in the research and development of products using protein in South Korea, Japan, Mexico, and internationally. It operates through Life and Health Business and Exosome Business divisions. The company offers products using stem cells. The company also provides cosmetics for hospitals and clinics, such as AAPE, a products containing high concentration human cell culture me… Read more
Prostemics Co. Ltd (203690) - Total Assets
Latest total assets as of September 2024: ₩62.86 Billion KRW
Based on the latest financial reports, Prostemics Co. Ltd (203690) holds total assets worth ₩62.86 Billion KRW as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Prostemics Co. Ltd - Total Assets Trend (2015–2023)
This chart illustrates how Prostemics Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Prostemics Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2023)
Prostemics Co. Ltd's total assets of ₩62.86 Billion consist of 54.1% current assets and 45.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 10.6% |
| Accounts Receivable | ₩3.96 Billion | 5.1% |
| Inventory | ₩4.56 Billion | 5.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩697.86 Million | 0.9% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2023)
This chart illustrates how Prostemics Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Prostemics Co. Ltd's current assets represent 54.1% of total assets in 2023, a decrease from 69.2% in 2015.
- Cash Position: Cash and equivalents constituted 10.6% of total assets in 2023, down from 15.4% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 5.9% of total assets.
Prostemics Co. Ltd Competitors by Total Assets
Key competitors of Prostemics Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Prostemics Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Prostemics Co. Ltd generates 0.48x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Prostemics Co. Ltd is currently not profitable relative to its asset base.
Prostemics Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.81 | 0.43 | 9.58 |
| Quick Ratio | 0.81 | 0.30 | 9.17 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-6.06 Billion | ₩ -20.76 Billion | ₩ 13.63 Billion |
Prostemics Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Prostemics Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.21 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 49.9% |
| Total Assets | ₩77.19 Billion |
| Market Capitalization | $34.15 Million USD |
Valuation Analysis
Below Book Valuation: The market values Prostemics Co. Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Prostemics Co. Ltd's assets grew by 49.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Prostemics Co. Ltd (2015–2023)
The table below shows the annual total assets of Prostemics Co. Ltd from 2015 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | ₩77.19 Billion | +49.94% |
| 2022-12-31 | ₩51.48 Billion | -3.17% |
| 2021-12-31 | ₩53.16 Billion | -11.65% |
| 2020-12-31 | ₩60.18 Billion | +89.00% |
| 2019-12-31 | ₩31.84 Billion | -4.42% |
| 2018-12-31 | ₩33.31 Billion | -17.92% |
| 2017-12-31 | ₩40.58 Billion | -13.76% |
| 2016-12-31 | ₩47.06 Billion | +8.72% |
| 2015-12-31 | ₩43.28 Billion | -- |